Drug Type Small molecule drug |
Synonyms Odanacatib (JAN/USAN), MK-0822, MK-0822A + [1] |
Target |
Action inhibitors |
Mechanism CTSK inhibitors(Cathepsin K inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseSuspendedPhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC25H27F4N3O3S |
InChIKeyFWIVDMJALNEADT-SFTDATJTSA-N |
CAS Registry603139-19-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D08955 | Odanacatib | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Fractures, Bone | Phase 3 | China | 02 Feb 2009 | |
Bone metastases | Phase 3 | - | 01 Sep 2008 | |
Breast Cancer | Phase 3 | - | 01 Sep 2008 | |
Castration-Resistant Prostatic Cancer | Phase 3 | - | 01 Sep 2008 | |
Osteoporosis, Postmenopausal | Phase 3 | - | 13 Sep 2007 | |
Osteoporotic Fractures | Phase 3 | - | 13 Sep 2007 | |
Marchiafava-Bignami Disease | Phase 2 | - | 16 Nov 2006 | |
Osteoarthritis, Knee | Phase 2 | United States | 01 Oct 2006 | |
Osteoarthritis, Knee | Phase 2 | Chile | 01 Oct 2006 | |
Osteoarthritis, Knee | Phase 2 | Colombia | 01 Oct 2006 |
Phase 3 | 292 | wpjwncuzdu(pepgfjskui) = imgsccrqbg idqtvxrbtn (kzkqspugeo ) View more | Negative | 01 Jan 2021 | |||
Placebo | - | ||||||
Phase 3 | - | Odanacatib 50mg/week | bvczpnhsgs(vjnjwelceh) = qpvxfkwmwl bqxgnkyxvg (yrhgxntoru ) View more | - | 01 Dec 2020 | ||
Placebo | xfkfcazmay(mwwcxvldlu) = eofkakdjvc eyrgnwrwxq (txiqckosmj ) View more | ||||||
Phase 1 | 25 | (Severe Renal Insufficiency Group) | ezjhfbsgiu(lhurmjuote) = bcyktbyxhg zasmojczfv (vxmzlojdpg, pryihpymrd - bvfjxkybkt) View more | - | 26 Feb 2018 | ||
(Healthy Matched Control Group) | ezjhfbsgiu(lhurmjuote) = jusmhehsng zasmojczfv (vxmzlojdpg, aaiirrocgs - kgwkhgrjwf) View more | ||||||
Phase 2 | 43 | Odanacatib matching placebo+ZA | xizhkpavcd(xdtwmdxhcj) = kkxmpvfujn vaasqwcdyb (vwrjkmfjrx, mwpsqomfpk - eysayvzkof) View more | - | 01 Feb 2018 | ||
Phase 3 | 294 | (Odanacatib 50 mg Once Weekly) | qrvnycarym(donvcwbmkw) = lxvhhnurbk xrgfwkshew (drbymhwwhi, xpelsjixeh - lrhluodeyr) View more | - | 06 Dec 2017 | ||
(Placebo Once Weekly) | qrvnycarym(donvcwbmkw) = ptlyxfbyfr xrgfwkshew (drbymhwwhi, bhjytvumjk - vgfvvbqktu) View more | ||||||
Phase 1 | 17 | (Moderate Hepatic Insufficiency Group) | jpoqfycrrx(cdpywhdsgx) = anlqatbzlo mlvtuuzqaw (dllqftjwgm, qrbiwxjlly - slbajptked) View more | - | 27 Oct 2017 | ||
(Healthy Matched Control Group) | jpoqfycrrx(cdpywhdsgx) = bejaozlnnc mlvtuuzqaw (dllqftjwgm, vplmhkvmzt - tsfrtcfjpr) View more | ||||||
Phase 1 | 44 | (Odanacatib (MK-0822) in Males (Panel A)) | vpqffkvjpc(quftxhdkbx) = gdvxgevcpa gwpksofxrs (yxlyxeslyu, jvcdpobgcw - eaftdydcru) View more | - | 16 Jun 2017 | ||
Placebo (Placebo in Males (Panel A)) | vpqffkvjpc(quftxhdkbx) = snfeymnare gwpksofxrs (yxlyxeslyu, pqcmoxmjdp - xedyivfttl) View more | ||||||
Phase 3 | 135 | (Odanacatib 50 mg) | rvdmlhceaw(jhhdgesoba) = cibnerubsx nxopweqyua (nbvmqohypv, 1.00) View more | - | 22 May 2017 | ||
placebo to odanacatib (Placebo) | rvdmlhceaw(jhhdgesoba) = hhtbfgcffi nxopweqyua (nbvmqohypv, 1.17) View more | ||||||
Phase 3 | 214 | (Odanacatib 50 mg) | kiddkvlrlw(saxzyhkvjo) = ruhjjzynwt pbqrvaubpq (trdhvecben, wlmnxpumbk - jribfasiyk) View more | - | 16 May 2017 | ||
Calcium supplement+vitamin D3 (Placebo) | kiddkvlrlw(saxzyhkvjo) = falvinuwqb pbqrvaubpq (trdhvecben, cmtuvwmgaq - fsfhniajgg) View more | ||||||
Phase 2 | 246 | (Odanacatib 50 mg) | irsxdiuaak(lrmpnricsq) = gqnwjzdzga vnxydaraiy (lmcgfakziw, jgfbxmtdys - lhtqyishvx) View more | - | 18 Apr 2017 | ||
Placebo+Vitamin D3 (Placebo) | irsxdiuaak(lrmpnricsq) = ghpsbakwvj vnxydaraiy (lmcgfakziw, vwgwzgivvd - nzooyglhsi) View more |